aTyr Pharma to present on efzofitimod at WASOG conference

aTyr Pharma announced that the company will present on its lead therapeutic candidate, efzofitimod, at the World Association for Sarcoidosis and Other Granulomatous Disorders, WASOG Conference, which is scheduled to take place June 19 – 21, 2023, in Stockholm, Sweden. “Efzofitimod is the most advanced investigational treatment in clinical development for sarcoidosis. With a novel myeloid-cell focused mechanism that downregulates inflammatory responses upstream of other targets, efzofitimod provides a differentiated approach to resolving inflammation and preventing the progression of fibrosis compared to existing treatments and others in development,” said Sanjay Shukla, M.D., M.S., President and CEO of aTyr. “The Phase 3 EFZO-FIT study, which is currently enrolling patients with pulmonary sarcoidosis in the U.S., Europe and Japan, is expected to be the largest interventional study in pulmonary sarcoidosis and represents an important step forward in developing a potential new treatment for patients with this debilitating disease.”